MTOR and type 2 diabetes mellitus: Metformin, a first-line oral antidiabetic agent for type 2 diabetes, has been found to play a potential role in anticancer effect through molecular mechanisms of the ATM/LKB1/AMPK axis and mammalian target of rapamycin (mTOR)-signaling pathway [13].